{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
The Ensign Group, Inc.
The Ensign Group Hits New 52-Week High of USD 188.25
The Ensign Group, Inc. has achieved a new 52-week high, reflecting its strong performance with a 55.81% return over the past year. With a market capitalization of USD 10,536 million, the company demonstrates financial stability, efficiency, and robust growth metrics in the Pharmaceuticals & Biotechnology sector.
The Ensign Group Experiences Revision in Stock Evaluation Amid Competitive Market Landscape
The Ensign Group, Inc. has recently adjusted its valuation, reflecting its financial metrics and market position. With a P/E ratio of 30 and a PEG ratio of 0.36, the company demonstrates a favorable growth outlook. Its competitive valuation metrics highlight its strength relative to industry peers.
Ensign Group's Valuation Upgrade Highlights Strong Financial Performance and Growth Potential
The Ensign Group, Inc. has recently experienced a change in its valuation grade, now deemed attractive. Key financial metrics reveal strong operational efficiency, healthy growth in net sales and operating profit, and solid figures for cash flow and interest coverage, highlighting the company's financial stability.
Is The Ensign Group, Inc. overvalued or undervalued?
As of October 17, 2025, The Ensign Group, Inc. is considered undervalued with an attractive valuation grade, featuring a P/E ratio of 30, an EV to EBITDA of 19.44, and a PEG ratio of 0.36, indicating potential growth compared to peers like Encompass Health Corp. and DaVita, Inc.
The Ensign Group Experiences Revision in Stock Evaluation Amid Strong Financial Performance
The Ensign Group, Inc. has recently adjusted its valuation, showcasing strong financial metrics such as a P/E ratio of 30 and a PEG ratio of 0.36. With a robust ROCE of 20.77% and a year-to-date return of 37.02%, the company demonstrates effective capital management and competitive positioning in its sector.
Is The Ensign Group, Inc. overvalued or undervalued?
As of October 17, 2025, The Ensign Group, Inc. is considered undervalued with a P/E ratio of 30 and a PEG ratio of 0.36, showing strong performance with a year-to-date return of 37.02%, significantly outperforming the S&P 500's 13.30%.
Is The Ensign Group, Inc. overvalued or undervalued?
As of October 17, 2025, The Ensign Group, Inc. is considered attractive due to its undervaluation despite a higher P/E ratio of 30, a strong growth potential indicated by a PEG ratio of 0.36, competitive EV to EBITDA ratio of 19.44, and impressive performance with a year-to-date return of 37.02% compared to the S&P 500's 13.30%.
The Ensign Group Hits New 52-Week High of $179.27
The Ensign Group, Inc. has achieved a new 52-week high, reflecting its strong performance with a one-year return significantly above the S&P 500. The company showcases robust financial metrics, including a solid return on equity and low debt-to-equity ratio, alongside consistent positive results in sales and operating profit growth.
The Ensign Group Hits New 52-Week High of $179.11
The Ensign Group, Inc. has achieved a new 52-week high, reflecting its strong performance in the Pharmaceuticals & Biotechnology sector. With a market capitalization of USD 10,536 million, the company shows robust operational efficiency, healthy growth in net sales and operating profit, and a solid balance sheet.
The Ensign Group Hits New 52-Week High of $176.59
The Ensign Group, Inc. has achieved a new 52-week high, reflecting its strong performance in the Pharmaceuticals & Biotechnology sector. With a market capitalization of USD 10,536 million, the company shows solid financial health, marked by a low debt-to-equity ratio and impressive growth in net sales and operating profit.
Is The Ensign Group, Inc. technically bullish or bearish?
As of August 5, 2025, The Ensign Group, Inc. shows a bullish trend supported by strong technical indicators, outperforming the S&P 500 with a year-to-date return of 25.75%, despite some mixed signals in longer-term indicators.
Is The Ensign Group, Inc. overvalued or undervalued?
As of July 29, 2025, The Ensign Group, Inc. is considered undervalued with a favorable valuation grade shift, reflected in its strong year-to-date return of 25.75% and a five-year return of 200.43%, despite a recent dip in stock performance.
Is The Ensign Group, Inc. overvalued or undervalued?
As of May 8, 2025, The Ensign Group, Inc. is considered overvalued with a P/E ratio of 30, significantly higher than its peers, indicating a shift from attractive to very expensive despite strong growth potential and recent stock performance.
Is The Ensign Group, Inc. technically bullish or bearish?
As of June 17, 2025, the market trend is mildly bullish, supported by bullish daily moving averages and weekly MACD, despite mixed signals from monthly indicators like MACD and KST.
Who are in the management team of The Ensign Group, Inc.?
As of March 2022, The Ensign Group, Inc.'s management team includes Co-Founder and Executive Chairman Christopher Christensen, CEO Barry Port, and several independent directors: Swati Abbott, Ann Blouin, Lee Daniels, and Daren Shaw. Roy Christensen serves as Chairman Emeritus.
What does The Ensign Group, Inc. do?
The Ensign Group, Inc. specializes in healthcare services, focusing on skilled nursing and rehabilitative services. As of March 2025, it reported net sales of $1.173 billion and a net profit of $80 million, with a market cap of approximately $9.28 billion.
How big is The Ensign Group, Inc.?
As of Jun 18, The Ensign Group, Inc. has a market capitalization of $9.28 billion, with net sales of $4.42 billion and a net profit of $309.85 million for the latest four quarters. The balance sheet as of Dec'24 shows shareholder's funds of $1.84 billion and total assets of $5.20 billion.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
